Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CCNC | P24863 | 1/20 | 0.38 |
| ▸ | CDK8 | P49336 | 1/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.37 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.37 |
| ▸ | FLT1 | P17948 | 1/20 | 0.37 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | CCR9 | P51686 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9400445 | 0.85 | MAPK1 (0.41) | ALDH1A1LMNACCNCCDK8PDGFRB | |
| SCHEMBL9400414 | 0.76 | MAPK1 (0.38) | ALDH1A1LMNAHPGDKDM4EMAPK1 | |
| SCHEMBL2312774 | 0.76 | FFAR1 (0.46) | ALDH1A1LMNACCNCCDK8HPGD | |
| SCHEMBL26115003 | 0.76 | KDM4E (0.45) | ALDH1A1HPGDKDM4EMAPK1TSHR | |
| SCHEMBL29792765 | 0.75 | ALDH1A1 (0.54) | ALDH1A1LMNACCNCCDK8KDM4E | |
| SCHEMBL19838578 | 0.75 | ALDH1A1 (0.54) | ALDH1A1LMNACCNCCDK8KDM4E | |
| SCHEMBL17948706 | 0.74 | KDM4E (0.42) | ALDH1A1HPGDKDM4ETSHRATM | |
| SCHEMBL25226721 | 0.74 | DPP4 (0.47) | ALDH1A1LMNAHPGDKDM4EMAPK1 | |
| SCHEMBL17490653 | 0.74 | KDM4E (0.44) | ALDH1A1HPGDKDM4EMAPK1TSHR | |
| SCHEMBL1915182 | 0.73 | ATM (0.41) | ALDH1A1LMNACCNCCDK8PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12221441-B2 | Plasma kallikrein inhibitors and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-02-11 | — | — | US | disclosed |
| EP-4477220-A2 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2024-12-18 | — | — | EP | disclosed |
| EP-4031547-B1 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-17 | — | — | EP | disclosed |
| EP-4031547-B1 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-17 | — | — | EP | disclosed |
| US-20230391773-A1 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-12-07 | — | — | US | disclosed |
| US-11787796-B2 | Plasma Kallikrein inhibitors and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-17 | — | — | US | disclosed |
| US-11787796-B2 | Plasma Kallikrein inhibitors and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-17 | — | — | US | disclosed |
| US-11787796-B2 | Plasma Kallikrein inhibitors and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-17 | — | — | US | disclosed |
| EP-4031547-A1 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2022-07-27 | — | — | EP | disclosed |
| CN-114728962-A | Plasma kallikrein inhibitors and uses thereof | 武田药品工业有限公司 | 2022-07-08 | — | — | CN | disclosed |
| WO-2021055621-A1 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2021-03-25 | — | — | WO | disclosed |
| US-20210078999-A1 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF | CHARLES RIVER LABORATORIES, INC. | 2021-03-18 | — | — | US | disclosed |
| US-20210078999-A1 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF | CHARLES RIVER LABORATORIES, INC. | 2021-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12221441-B2 | Plasma kallikrein inhibitors and uses thereof | KLKB1, KLK1, KLK5 | ALDH1A1 3007/4885LMNA 1626/4885CCNC 4342/4885 |
| US-11787796-B2 | Plasma Kallikrein inhibitors and uses thereof | KLKB1, KLK1, KLK5 | ALDH1A1 3007/4885LMNA 1626/4885CCNC 4342/4885 |
| US-20230391773-A1 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF | KLKB1, KLK1, KLK5 | ALDH1A1 3007/4885LMNA 1626/4885CCNC 4342/4885 |
| US-20210078999-A1 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF | KLKB1, KLK1, KLK5 | ALDH1A1 3007/4885LMNA 1626/4885CCNC 4342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.